<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000400012</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20220004000012</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Instrumentos de avaliação da neuropatia periférica induzida por quimioterapia no paciente com mieloma múltiplo]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation instruments of peripheral neuropathy induced by chemotherapy in patients with multiple myeloma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueiredo-Modesto]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medrado-e Silva]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cordeiro-de Farias]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pandolfo-Provin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeida-Matteucci-Ferreira]]></surname>
<given-names><![CDATA[TX]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade Federal de Goiás Hospital das Clínicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Federal de Goiás Hospital das Clínicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade Federal de Goiás Hospital das Clínicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidade Federal de Goiás Faculdade de Farmácia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>4</numero>
<fpage>387</fpage>
<lpage>393</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000400012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000400012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000400012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo: Identificar instrumentos de avaliação da neuropatia periférica induzida por quimioterapia que possam ser traduzidos ou adaptados para monitoramento dessa reação adversa a medicamentos em pacientes com mieloma múltiplo.  Método: Revisão narrativa, realizada entre julho de 2018 a maio de 2019. Foram elegíveis artigos publicados em inglês e português, entre junho de 2007 a janeiro de 2019, disponíveis na íntegra de maneira livre ou em periódicos do Portal da CAPES Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Foram excluídos estudos com animais, monografias, guidelines, teses, casos clínicos e estudos que não da área de saúde.  Resultados: Foram identificados cinco instrumentos: Patient Neurotoxicity Questionnaire; Funcional Assessment of Cancer Therapy/ Gynecologyc Group &#8211; Neurotoxicity; Chemotherapy-Induced Peripheral Neuropathy Assessment Tool; Funcional Assessment Cancer Therapy/Taxane; Indication for Common Toxicity Criteria &#8211; Grading of Peripheral Neuropathy Questionnaire (ICPNQ). Após análise de cada ferramenta apresentada, o ICPNQ se mostrou válido e aplicável na prática clínica, porém, encontra-se em língua inglesa.  Conclusão: A tradução e validação do instrumento ICPNQpara o português, possibilitaria sua incorporação à práticaclínica no monitoramento da neuropatia periférica induzidapor quimioterapia em pacientes com Mieloma Múltiplo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary  Objective: To identify instruments for evaluation of peripheral neuropathy induced by chemotherapy that can be translated or adapted to monitor this adverse drug reaction in patients with multiple myeloma.  Method: Narrative review, conducted between July 2018 and may 2019. Articles published in English and Portuguese were eligible between June2007 and January 2019, available in full in a free manner or in periodicals of the CAPES Coordination Portal for Improvement of Level Personnel Higher. Animal studies, monographs, guidelines, theses, clinical cases and non-health studies were excluded.  Results: Five instruments were identified:Patient Neurotoxicity Questionnaire;Funcional Assessment of Cancer Therapy/Gynecologyc Group &#8211; Neurotoxicity;Chemotherapy-Induced Peripheral NeuropathyAssessment Tool; Funcional AssessmentCancer Therapy/Taxane; Indicationfor Common Toxicity Criteria &#8211; Grading ofPeripheral Neuropathy Questionnaire (ICPNQ). After analyzing each tool presented,the ICPNQ proved to be valid andapplicable in clinical practice, however, itis in the English language.  Conclusion: The translation and validation of the ICPNQ instrument into Portuguese would allow its incorporation into clinical practice in the monitoring of peripheral neuropathy induced by chemotherapy in patients with multiple myeloma.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Efeitos colaterais e reações adversas relacionados a medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[antineoplásicos]]></kwd>
<kwd lng="pt"><![CDATA[tratamento farmacológico]]></kwd>
<kwd lng="pt"><![CDATA[doenças do sistema nervoso periférico]]></kwd>
<kwd lng="pt"><![CDATA[doenças hematológicas]]></kwd>
<kwd lng="en"><![CDATA[Drug-related side effects and adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[antineoplastic agents]]></kwd>
<kwd lng="en"><![CDATA[drug therapy]]></kwd>
<kwd lng="en"><![CDATA[peripheral nervous system diseases]]></kwd>
<kwd lng="en"><![CDATA[hematologic diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Instituto Nacional do Câncer</collab>
<source><![CDATA[Estimativa 2018: incidência de câncer no Brasil]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dikshit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rebelo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2015</year>
<volume>136</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>359-86</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffbrand]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[PAH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiologia e genética das hemopatias malignas]]></article-title>
<source><![CDATA[Fundamentos em Hematologia]]></source>
<year>2013</year>
<edition>6</edition>
<page-range>151-4</page-range><publisher-loc><![CDATA[Porto Alegre ]]></publisher-loc>
<publisher-name><![CDATA[Artmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Frizzo]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoplasias hematológicas no idoso: uma revisão]]></article-title>
<source><![CDATA[Revista Saúde Integrada]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>15-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Rajkumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kyle]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Van Duin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sonneveld]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple myeloma]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2017</year>
<volume>3</volume>
<numero>17046</numero>
<issue>17046</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Bomfim]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterização dos sinais e sintomas clínicos do mieloma múltiploe os atuais métodos de diagnóstico laboratorial]]></article-title>
<source><![CDATA[Revista UNINGÁ Review]]></source>
<year>2015</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zago]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Falcão]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Pasquini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distúrbios dos plasmócitos e seus precursores]]></article-title>
<source><![CDATA[Tratado de hematologia]]></source>
<year>2013</year>
<page-range>553-68</page-range><publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
<publisher-name><![CDATA[Atheneu]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ludwig]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Miguel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Palumbo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Sanz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Powles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Myeloma Working Group recommendations for global myeloma care]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2014</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>981-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Expósito Vizcaíno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Casanova-Mollà]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Escoda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Galán]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Miró]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dolor neuropático en pacientes oncológicos en tratamiento con bortezomib]]></article-title>
<source><![CDATA[Neurologia]]></source>
<year>2018</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>28-34</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerckhove]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Collin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Condé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chaleteix]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pezet]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balayssac]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology]]></article-title>
<source><![CDATA[Bull Cancer]]></source>
<year>2018</year>
<volume>105</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1020-32</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rother]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisão sistemática x revisão narrativa]]></article-title>
<source><![CDATA[Acta pau]]></source>
<year>2007</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[KDS]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[RCCP]]></given-names>
</name>
<name>
<surname><![CDATA[Galvão]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem]]></article-title>
<source><![CDATA[Texto &amp; Contexto Enfermagem]]></source>
<year>2008</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>758-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Friedlander]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of oxaliplatin-induced neuropathy: A patient perspective]]></article-title>
<source><![CDATA[Supportive Care Cancer]]></source>
<year>2012</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2959-67</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimozuma]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ohashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aranishi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kuroi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: NSAS BC 02]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2009</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1483-91</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cella]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Homesley]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Montag]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Geest]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2019</year>
<volume>119</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>538-42</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hon]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Orsini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sakai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer]]></article-title>
<source><![CDATA[J Thorac Oncol]]></source>
<year>2014</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-90</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tofthagen]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Kip]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool]]></article-title>
<source><![CDATA[Cancer Nurs]]></source>
<year>2011</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>E10-20</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kutlutürkan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Öztürk]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Kahraman]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Özcan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Uçar]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The psychometric properties of the Turkish version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT)]]></article-title>
<source><![CDATA[Eur J Oncol Nurs]]></source>
<year>2017</year>
<volume>31</volume>
<page-range>84-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beijers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vreugdenhil]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Oerlemans]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eurelings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Minnema]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Eeltink]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice]]></article-title>
<source><![CDATA[Supportive Care in Cancer]]></source>
<year>2016</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2411-20</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simão]]></surname>
<given-names><![CDATA[DAS]]></given-names>
</name>
</person-group>
<source><![CDATA[Avaliação de monofilamentos de Semmes-Weinstein e de um questionário de neurotoxicidade como instrumentos de detecção de neuropatia periférica induzida por quimioterapia]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Belo Horizonte ]]></publisher-loc>
<publisher-name><![CDATA[Universidade de Minas Gerais]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zandonai]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<source><![CDATA[Adaptação transcultural e validação do instrumento Chemoterapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) para o Brasil]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Ribeirão Preto ]]></publisher-loc>
<publisher-name><![CDATA[Universidade de São Paulo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[EML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current methods for the assessment and management of taxane-related neuropathy]]></article-title>
<source><![CDATA[Clin J Oncol Nurs]]></source>
<year>2013</year>
<volume>17</volume>
<numero>Suppl</numero>
<issue>Suppl</issue>
<page-range>22-34</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curcio]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy]]></article-title>
<source><![CDATA[Clin J Oncol Nurs]]></source>
<year>2016</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>144-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
